Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | CDC14B | O60729 | 1/20 | 0.30 |
| ▸ | CDC14A | Q9UNH5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19862847 | 1.00 | MEN1 (0.33) | MEN1ALDH1A1POLBTSHRBRCA1 | |
| SCHEMBL18594359 | 1.00 | MEN1 (0.33) | MEN1ALDH1A1POLBTSHRBRCA1 | |
| SCHEMBL19862856 | 0.99 | ALDH1A1 (0.33) | MEN1ALDH1A1POLBTSHRBRCA1 | |
| SCHEMBL19862934 | 0.98 | ALDH1A1 (0.35) | MEN1ALDH1A1POLBTSHRBRCA1 | |
| SCHEMBL19862941 | 0.98 | ALDH1A1 (0.35) | MEN1ALDH1A1POLBTSHRBRCA1 | |
| SCHEMBL19862962 | 0.98 | ALDH1A1 (0.35) | MEN1ALDH1A1POLBTSHRBRCA1 | |
| SCHEMBL19862944 | 0.97 | ALDH1A1 (0.35) | MEN1ALDH1A1POLBTSHRBRCA1 | |
| SCHEMBL19862960 | 0.97 | ALDH1A1 (0.35) | MEN1ALDH1A1POLBTSHRBRCA1 | |
| SCHEMBL19862933 | 0.97 | ALDH1A1 (0.35) | MEN1ALDH1A1POLBTSHRBRCA1 | |
| SCHEMBL19862930 | 0.96 | ALDH1A1 (0.36) | MEN1ALDH1A1POLBTSHRBRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10230056-B2 | Heterocyclic compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2019-03-12 | — | — | US | disclosed |
| US-20180047914-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-02-15 | — | — | US | disclosed |
| US-20180047914-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10230056-B2 | Heterocyclic compound and organic light emitting element comprising same | CRY1, CRY2, NR2E3 | MEN1 798/4885ALDH1A1 242/4885POLB 3598/4885 |
| US-20180047914-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | CRY1, CRY2, NR2E3 | MEN1 798/4885ALDH1A1 242/4885POLB 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.